Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment

Summary & key facts

Researchers interviewed 21 adults with post-traumatic stress disorder who took part in a phase 2 trial of a single, supported dose of psilocybin. Participants had guided preparation, one in-person psilocybin session, and follow-up meetings. In interviews done before treatment, the day after, and three months later, people described feeling safe when the team provided clear information and support. Many said the psilocybin session let them face trauma in different ways than normal therapy—sometimes by directly recalling memories, and sometimes through strong feelings, bodily sensations, or moments of feeling connected to something bigger than themselves. The study is small and not controlled, so the findings are about what participants experienced, not proof that psilocybin works for PTSD.

Key facts:

• This study talked in depth with 21 people who had PTSD and who joined a larger safety trial of an investigational psilocybin treatment.
• Each participant had standard preparation, one supervised psilocybin session, and follow-up integration sessions.
• Interviewers spoke with participants before treatment, the day after the psilocybin session, and 12 weeks later to learn about their experiences.
• Researchers found four main themes: the importance of safety and trust, the strongly experiential nature of psilocybin, ways participants engaged with trauma during the session, and how psilocybin differed from prior therapies.
• Participants described two kinds of trauma engagement during psilocybin: direct recall of traumatic memories, and indirect engagement through strong emotions, body sensations, or self-transcendent moments like feeling unity or a loss of the usual sense of self.
• Many people said clear preparation, monitoring, and support helped them feel safe and able to engage with difficult material during the session.
• The study is an open-label, qualitative sub-study, which means it reports what participants said about their experience but does not provide controlled evidence that psilocybin reduces PTSD symptoms.
• The authors say larger, controlled studies that combine symptom measures with people’s stories are needed before firm conclusions can be drawn.

Abstract

Compass Pathways, plc.

Topics

Pain Management and Placebo Effect Paranormal Experiences and Beliefs Psychedelics and Drug Studies

Categories

Clinical Psychology Psychology Social Sciences

Tags

Acute Stress Disorder Clinical psychology Clinical trial Compass Investigational Drugs Medicine MEDLINE Physical therapy Posttraumatic stress Psilocybin Psychiatry Psychotherapist Qualitative analysis Qualitative research Stress (linguistics) Traumatic stress

Substances

Psilocybin

Conditions & symptoms

Depression PTSD Feeling disconnected from others Sadness or low mood